TNF receptor‐associated factor 1 as a biomarker for assessment of non‐small cell lung cancer metastasis and overall survival. (24th March 2018)

• Record Type: Journal Article
• Authors: Wen, Xiaoxing; Wang, Bingping; Feng, Tao; Yuan, Wei; Zhou, Jian; Fang, Tao
• Is Part Of: Clinical respiratory journal. Volume 12:Number 7(2018)
• Page Start: 2197
• Page End: 2203
• Publication Date: 2018-03-24
• Subjects: metastasis -- non‐small cell lung cancer -- overall survival -- TRAF1; Respiratory organs -- Diseases -- Periodicals; Respiratory organs -- Periodicals; 616.24
• DOI: 10.1111/crj.12789
• Languages: English
• ISSNs: 1752-6981

Abstract

Abstract: Background and aim: Non‐small cell lung cancer (NSCLC), which comprises 80%‐85% of all lung cancer cases, is one of the most common human malignancies. Despite great improvements in diagnostic technology and the introduction of new therapeutic agents in recent years, the 5‐year survival rate of NSCLC is still low. Tumor necrosis factor (TNF) receptor‐associated factor 1 (TRAF1) plays an important role in the TNF‐related apoptosis‐inducing ligand (TRAIL) associated signal pathway. Methods: In this study, we aim to illuminate the function of TRAF1 in NSCLC. Toward that end, TRAF1 expression was detected using immunohistochemistry (IHC) in specimens from 200 NSCLC patients. The function of TRAF1 in the A549 and H1299 cell lines was evaluated by colony formation and MTT assays. Results: Our data showed that TRAF1 was significantly upregulated in NSCLC tissues. TRAF1 expression was positively associated with NSCLC lymphatic metastasis and clinical stage and was negatively associated with overall patient survival. TRAF1 promoted NSCLC cell proliferation Conclusion: TRAF1 expression was positively associated with NSCLC lymphatic metastasis and histological grade and was negatively associated with overall patient survival. TRAF1 may be an important therapeutic target for NSCLC.